Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
Open Access
- 3 July 2023
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 23 (1) , 1-8
Abstract
Purpose: MET exon 14 skipping is one of the rare mutations in non-small cell lung cancer (NSCLC), involving its pathogenesis and progression. The performances of several MET inhibitors in clinical trials have been validated based on NGS, immunohistochemistry (IHC), and gene copy number assessments. Thus, a detailed understanding of the relationship between these markers and prognosis is required. Methods: This study has recruited patients (n = 17) with MET exon 14 skipping mutation and initially screened genes (n = 10) by polymerase chain reaction (PCR) from 257 specimens of NSCLC, including small biopsies and surgical resection. Further, the IHC analysis detected MET overexpression and recorded the score using the MetMAb trial (rial ( recruited patients (n = 17) with MET exstainings). Finally, the fluorescence in situ hybridization (FISH) resulted in the MET amplification with a MET copy number initially screened genes (n = 10) by p. Results: PCR results indicated strong MET staining ( 3+) in more than 50% of tumor cells. Among the recruited 17 cases of MET exon 14 skipping, 9 cases presented MET amplification, and 10 cases with MET overexpression. These attributes were not correlated to the clinicopathological characteristics and overall survival. In addition, 4 cases showed gene amplification, and 3 cases presented polyploidy condition. The correlation analysis showed a significant relationship between MET amplification and MET overexpression (Pearson’s r2 = 0.4657, P < 0.005). Conclusion: Together, these findings indicated a significant correlation between MET overexpression and MET amplification in NSCLC patients but no correlation to prognosis.Keywords
Funding Information
- Role and mechanism of POXC1 regulating PRAME to promote invasion and migration of breast cancer cells (S2021-YF-YBSF-0426 POXC1)
This publication has 20 references indexed in Scilit:
- HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancersCritical Reviews in Clinical Laboratory Sciences, 2019
- Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2019
- DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung CancerJournal of Thoracic Oncology, 2019
- Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implicationsInternational Journal of Medical Sciences, 2019
- Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysisLung Cancer, 2018
- Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapyNature Reviews Cancer, 2018
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping AlterationsJournal of Thoracic Oncology, 2016
- MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor PrognosisClinical Cancer Research, 2016
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met OverexpressionJournal of Clinical Oncology, 2016
- MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)Oncotarget, 2015